Form 4: Liquidia CMO Sells 20,000 Shares Under 10b5-1 Plan

Liquidia Corporation's Chief Medical Officer, Rajeev Saggar, sold 20,000 shares of common stock for approximately $27.85 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Rajeev Saggar, Chief Medical Officer of Liquidia Corp, sold 20,000 shares of common stock.
• The transaction occurred on August 28, 2025, at a volume-weighted average price of $27.8536 per share, with prices ranging from $27.22 to $28.53.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2025.
• Following the transaction, Dr. Saggar beneficially owns 249,727 shares directly.
• This remaining beneficial ownership includes 31,249 unvested RSUs from a January 11, 2023 grant, 35,307 unvested RSUs from a January 11, 2024 grant, 71,780 unvested RSUs from a January 11, 2025 grant, and 7,131 shares acquired through the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 4

Explanation: The sale by a key executive, even under a 10b5-1 plan, can be viewed with slight caution by investors. However, the pre-planned nature and the remaining significant beneficial ownership mitigate a strongly negative sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than an immediate reaction to market events, which can sometimes mitigate negative interpretations of insider selling.

Negatives

• An insider, specifically the Chief Medical Officer, sold a significant number of shares (20,000 shares).
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it might suggest a lack of confidence in the company's near-term prospects, or simply a diversification/liquidity event.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sale of 20,000 common stock shares by Chief Medical Officer Rajeev Saggar to the open market, considered a related party transaction due to insider status.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially leading to minor negative sentiment or increased scrutiny, though the 10b5-1 plan mitigates immediate concerns.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

While an insider sale by a Chief Medical Officer could be a cause for concern, the transaction was executed under a pre-arranged 10b5-1 plan, suggesting it was not a reaction to new, negative information. The executive still retains a substantial beneficial ownership, including a significant number of unvested RSUs, indicating continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future developments rather than making immediate buy or sell decisions based solely on this filing.

Keywords

Liquidia Corp, LQDA, Insider Sale, Form 4, Rajeev Saggar, Chief Medical Officer, 10b5-1 Plan, Stock Transaction, Equity Disposal